Clifford A. Hudis, MD, describes ASCO's CancerLinQ program, which is a direct response to the Insitute of Medicine's call for rapid learning systems.
Clifford A. Hudis, MD, ASCO President-Elect, Chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, describes the American Society of Clinical Oncology's (ASCO) CancerLinQ program.
The CancerLinQ program is a direct response to the Insitute of Medicine's call for rapid learning systems, Hudis says. Right now, 97% of patients who have solid tumors in adulthood are not treated on any clinical trial. Seventy-five percent of these patients are treated in systems with electronic medical records, indicating a potential to gain something out of those data that are already being well reported. The problem, Hudis says, is that electronic medical records do not use standards or communicate with one another.
CancerLinQ will improve quality of care by giving physicians the ability to gauge how they are doing against guidelines. Consequently, CancerLinQ can provide better cost control, better efficiency, and do away with complex layers of auditing and redundancy in the current medical record system.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More